See more : Svenska Handelsbanken AB (publ) (SHB-B.ST) Income Statement Analysis – Financial Results
Complete financial analysis of SOPHiA GENETICS SA (SOPH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SOPHiA GENETICS SA, a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- ISP Global Limited (8487.HK) Income Statement Analysis – Financial Results
- Info Yatirim Menkul Degerler A.S. (INFO.IS) Income Statement Analysis – Financial Results
- GEPIC Energy Development Co., Ltd. (000791.SZ) Income Statement Analysis – Financial Results
- Wong’s Kong King International (Holdings) Limited (0532.HK) Income Statement Analysis – Financial Results
- Isoray, Inc. (ISR) Income Statement Analysis – Financial Results
SOPHiA GENETICS SA (SOPH)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.sophiagenetics.com
About SOPHiA GENETICS SA
SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 62.37M | 47.56M | 40.45M | 28.40M | 25.36M |
| Cost of Revenue | 19.46M | 16.31M | 15.23M | 10.71M | 7.53M |
| Gross Profit | 42.91M | 31.25M | 25.22M | 17.69M | 17.83M |
| Gross Profit Ratio | 68.80% | 65.71% | 62.35% | 62.29% | 70.30% |
| Research & Development | 36.97M | 35.37M | 26.58M | 18.59M | 15.02M |
| General & Administrative | 53.30M | 55.82M | 41.51M | 18.97M | 15.67M |
| Selling & Marketing | 28.42M | 28.27M | 28.74M | 17.43M | 19.41M |
| SG&A | 81.72M | 84.08M | 70.24M | 36.40M | 35.08M |
| Other Expenses | -954.00K | -377.00K | -108.00K | -129.00K | 16.00K |
| Operating Expenses | 117.74M | 119.08M | 96.71M | 54.86M | 50.12M |
| Cost & Expenses | 137.20M | 135.38M | 111.94M | 65.57M | 57.65M |
| Interest Income | 4.55M | 1.32M | 20.00K | 96.00K | 86.00K |
| Interest Expense | 588.00K | 639.00K | 658.00K | 840.00K | 976.00K |
| Depreciation & Amortization | 8.34M | 5.57M | 3.61M | 2.39M | 1.91M |
| EBITDA | -70.70M | -82.67M | -70.84M | -38.76M | -30.74M |
| EBITDA Ratio | -113.35% | -172.94% | -167.76% | -122.11% | -119.42% |
| Operating Income | -74.83M | -87.82M | -71.49M | -37.17M | -32.29M |
| Operating Income Ratio | -119.97% | -184.66% | -176.73% | -130.86% | -127.30% |
| Total Other Income/Expenses | -3.67M | 238.00K | -2.02M | -3.84M | -1.34M |
| Income Before Tax | -78.50M | -87.59M | -73.51M | -41.23M | -33.63M |
| Income Before Tax Ratio | -125.85% | -184.16% | -181.72% | -145.16% | -132.60% |
| Income Tax Expense | 486.00K | -136.00K | 168.00K | -1.89M | 162.00K |
| Net Income | -78.98M | -87.45M | -73.68M | -39.34M | -33.79M |
| Net Income Ratio | -126.63% | -183.87% | -182.14% | -138.52% | -133.23% |
| EPS | -1.22 | -1.36 | -1.15 | -0.62 | -0.53 |
| EPS Diluted | -1.22 | -1.36 | -1.15 | -0.62 | -0.53 |
| Weighted Avg Shares Out | 64.75M | 64.10M | 63.86M | 63.86M | 63.86M |
| Weighted Avg Shares Out (Dil) | 64.75M | 64.10M | 63.86M | 63.86M | 63.86M |
SOPHiA GENETICS to Present at the Barclays 26th Annual Global Healthcare Conference
BOSTON and ROLLE, Switzerland, March 07, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced Chief Financial Officer and Chief Operating Officer, Ross Muken, will participate in a fireside...
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2023 Results
Strong momentum to continue in 2024 as SOPHiA GENETICS announces record revenue, 35 new customer additions in Q4, and 36% cash burn decline in FY 2023 Strong momentum to continue in 2024 as SOPHiA GENETICS announces record revenue, 35 new...
SOPHiA GENETICS to Participate in Fireside Chat at the 44th Annual TD Cowen Health Care Conference
BOSTON and ROLLE, Switzerland, Feb. 22, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced Co-founder and Chief Executive Officer, Dr. Jurgi Camblong, and Chief Financial Officer and Chief...
SOPHiA GENETICS to Announce Financial Results for the Fourth Quarter and Full-Year 2023 on March 5, 2024
BOSTON and ROLLE, Switzerland, Feb. 20, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full-year 2023 before...
SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain
SOPHiA GENETICS and AstraZeneca Spain expand HRD testing program to support molecular diagnosis of ovarian cancer in Spain BOSTON and ROLLE, Switzerland and MADRID , Feb. 7, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a...
SOPHiA GENETICS Supports Genetic Testing in Brazil
The company announced Bioma4me has implemented SOPHiA DDM™ to support its rare disorder testing capabilities BOSTON and ROLLE, Switzerland , Jan. 25, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader...
SOPHiA GENETICS Enhances RareCyte Precision Biology Services Portfolio
RareCyte will use the SOPHiA DDM™ Platform to support its oncology testing panel BOSTON and ROLLE, Switzerland , Jan. 18, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that RareCyte...
SOPHiA GENETICS and Karkinos Healthcare Forge Strategic Partnership to Advance Cancer Research in India
SOPHiA GENETICS technology helps advance cancer research across India SOPHiA GENETICS and Karkinos Healthcare join forces to propel cutting-edge genomic solutions for breakthroughs in personalized cancer care in India BOSTON and ROLLE, Switzerland , Jan. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq:...
SOPHiA GENETICS Highlights Near-Term Growth Strategy at 42nd Annual J.P. Morgan Healthcare Conference
Strong SOPHiA DDM™ adoption and analysis volume contributes to continued revenue growth Liquid biopsy and HRD on SOPHiA DDM™ Platform continue to grow year-over-year, with Tennessee Oncology, Dasa and The Royal Marsden announced today BOSTON and ROLLE, Switzerland , Jan....
Exactis Innovation and SOPHiA GENETICS Announce Collaboration on Multimodal Data Analytics
Insights from multimodal datasets on the platform fuel cancer research in Canada BOSTON and ROLLE, Switzerland , Jan. 8, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced a collaboration...
Source: https://incomestatements.info
Category: Stock Reports